Compare · ABBV vs TEVA
ABBV vs TEVA
Side-by-side comparison of AbbVie Inc. (ABBV) and Teva Pharmaceutical Industries Limited (TEVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and TEVA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $469.68B, about 10.6x TEVA ($44.40B).
- ABBV has been more active in the news (17 items in the past 4 weeks vs 8 for TEVA).
- Both have 25 recent analyst ratings on file.
- Company
- AbbVie Inc.
- Teva Pharmaceutical Industries Limited
- Price
- -
- -
- Market cap
- $469.68B
- $44.40B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2012
- News (4w)
- 17
- 8
- Recent ratings
- 25
- 25
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Latest ABBV
- AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
- EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas sold $8,177,500 worth of shares (32,710 units at $250.00) and exercised 32,710 shares at a strike of $79.02 (SEC Form 4)
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
- AbbVie upgraded by Wolfe Research with a new price target
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices
- SEC Form 424B5 filed by AbbVie Inc.
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest TEVA
- Chief Accounting Officer Weiss Amir sold $355,301 worth of Ordinary Shares (9,445 units at $37.62) and exercised 2,500 units of Ordinary Shares at a strike of $19.61, decreasing direct ownership by 35% to 13,071 units (SEC Form 4)
- Director Satchi-Fainaro Ronit sold $15,459 worth of Ordinary Shares (415 units at $37.25), decreasing direct ownership by 0.37% to 111,986 units (SEC Form 4)
- EVP, Business Development Lippman Evan sold $680,291 worth of Ordinary Shares (18,600 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 42% to 25,591 units (SEC Form 4)
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
- Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
- Director Zaks Tal Zvi sold $593 worth of Ordinary Shares (17 units at $34.87), decreasing direct ownership by 0.02% to 73,247 units (SEC Form 4)
- See "Remarks" Jover Placid converted options into 12,827 units of Ordinary Shares and sold $447,351 worth of Ordinary Shares (12,827 units at $34.88) as part of a pre-agreed trading plan (SEC Form 4)
- See "Remarks" Hughes Eric A converted options into 52,744 units of Ordinary Shares and sold $892,051 worth of Ordinary Shares (25,578 units at $34.88) as part of a pre-agreed trading plan, increasing direct ownership by 25% to 134,877 units (SEC Form 4) (for withholding tax)
- SEC Form 10-Q filed by Teva Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits